Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues

Nanoparticle Development Services for Drug Delivery System Research

Creative Biogene Delivers Knockout Mouse Models to Support Gene Editing and Future Studies

Acylation Reagents for Gas Chromatography and Other Instrumental Analytical Methods

ExoQuali Products and Protocols Released by Creative Bioarray to Easy Exosome Isolation Process

Histobiolab Provides Over 150 Fish Probes to Satisfy Precise Biological Research Needs

Creative Bioarray Provides 3D Cell Patterning Service Based to Speed up Drug Screening

PubHive Upgrades SaaS Platform to MedDRA Version 25.1

Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities

Terumo Pharmaceutical Solutions expands CDMO services outside Japan for global market

Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.

MULTI-LEVEL & MULTI-ANALYTE LIQUID STABLE CLINICAL ENZYME CALIBRATION VERIFIERS AVAILABLE FROM VERICHEM

CARLSBAD, Calif. (Oct. 31, 2022) – Thermo Fisher Scientific introduces new dPCR wastewater surveillance kit and RNA master mix to simplify detection of SARS-CoV-2 targets

New NoriZite™ Nasal Spray launches in the UK

Birmingham Biotech LTD, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces that NoriZite™ Nasal Spray, an easy-to-use nasal device designed to block and trap inhaled virus particles, is now available to buy in the UK.

Samsung Biologics Reports Third Quarter 2022 Financial Results

Samsung Biologics reports third quarter 2022 financial results

Abundent Application Potentials of Nanomaterials

Alfa Chemistry Announces Offering of Low Molecular Weight Carboxylic Acids

CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

AtlantiCare Implements Orbita’s Healthcare Virtual Assistants to Enhance Access to Care

Andelyn Biosciences announces opening of its state-of-the-art GMP manufacturing facility to meet industry demand

Contact information Eric Blair, Chief Commercial Officer Eric.Blair@AndelynBio.com For media enquiries, please contact Imogen Quail, PR Manager, imogen.quail@ramarketingpr.com, ramarketingpr.com About Andelyn Biosciences, Inc. Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and drug product manufacturing services. Having 20+ years of experience in viral vector manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders that have enabled 75+ worldwide clinical trials. With the experience gained from over 400 cGMP clinical batches and 2000+ research-grade productions, Andelyn provides its clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply chain vertical integration. Andelyn began operations in its state-of-the-art 200,000 sq. ft. commercial manufacturing facility in September 2022, expanding capacity across 14+ production suites for customization of new programs and tech transferred programs. Andelyn is one of a few select CDMOs that offer clinical through commercial-scale capabilities that will help fulfil Andelyn’s mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Andelyn is owned and supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of Danaher Corporation.

Conclusions of the 7th Crystal Structure Prediction Blind Test

• Seven structures of 2D systems that had been experimentally analysed but not published (‘blind’) released to participants along with some experimental conditions. • Boundaries pushed beyond the pharmaceutical sector to areas such as electronics and photonics with the inclusion of an optoelectronic system containing silicon and a metal-organic system containing copper. • Also included one of the most challenging systems in CSP Blind Test history - a large, highly polymorphic, phamaceutical drug candidate. • Test ran from October 2020 to September 2022. • More experimental data released over the course of the test to simulate real world conditions. • Submissions received from industrial and academic groups worldwide. • All compounds successfully had their experimentally observed crystal structures predicted from landscapes of 1K+ potential structures. • PXRD challenge showcased the application of CSP to industrially relevant molecules.

Inizio commits to helping limit the impact of climate change and achieving SBTi Net-Zero Standard

Inizio commits to SBTi Net-Zero Standard